

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

į,

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.
09/007,09		ANAND		N	1038-765-MIS
	\ I'''`\	HM11/1222	٦	Not	EXAMINER AN, P

SIM & BURNEY SUITE 701 330 UNIVERSITY AVNEUE TORONTO ON MSG 1R7 CANADA

ART UNIT	PAPER NUMBER
1644	

AIR MAIL

DATE MAILED: 12/22/98

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

	Application No. 09/007,093	Applicant(s)	ANAND			
Office Action Summary	Examiner 1644		Group Art Unit			
—The MAILING DATE of this communication appear	s on the cover sheet b	eneath the cor	respondence	address		
eriod for Response	-20 da	Mrs. MONTH	40) FROM TU	=		
eriod for Response SHORTENED STATUTORY PERIOD FOR RESPONSE IS SI IAILING DATE OF THIS COMMUNICATION.						
 Extensions of time may be available under the provisions of 37 CFR 1 from the mailing date of this communication. If the period for response specified above is less than thirty (30) days, If NO period for response is specified above, such period shall, by def. Failure to respond within the set or extended period for response will, 	a response within the statute	ory minimum of thi	rty (30) days will date of this comm	be considered timely. nunication .		
Status						
Responsive to communication(s) filed on				•		
 ☐ This action is FINAL. ☐ Since this application is in condition for allowance except accordance with the practice under Ex parte Quayle, 193 	for formal matters, pro 5 5 C.D. 1 1; 453 O.G. 21	secution as to	tue menta ia			
Disposition of Claims		6	dina in the	application		
(Claim(s)		is/are pending in the application.				
Disposition of Claims Claim(s)		is/are \	withdrawn from	Consideration.		
Claim(s)		is/are a	alloweu.			
		is/are i	reiected.			
□ Claim(s)	,	is/are	objected to.			
□ Claim(s) □ Claim(s) -2\(\sigma\) 27-28		are su require	bject to restric ement.	tion or election		
Application Papers						
☐ See the attached Notice of Draftsperson's Patent Drawi	ng Review, PTO-948.	d	ad			
☐ The proposed drawing correction, filed on	is approved		,u.			
☐ The drawing(s) filed on is/are objectively.	cled to by the Examinor	1•				
☐ The specification is objected to by the Examiner.						
☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. § 119 (a)-(d)		'a\-(d\				
 □ Acknowledgment is made of a claim for foreign priority □ All □ Some* □ None of the CERTIFIED copies of received. 	of the priority documents	S nave been				
 received in Application No. (Series Code/Serial Num received in this national stage application from the li 	nternational Bureau (PC	, I Hule 1 7.2(a)	<i>)</i> •			
*Certified copies not received:						
"Certified copies not received.			D=0 1	40		
Attachment(s)		The base of the City	nmary, PTO-4	13		
Attachment(s)	(- / -			entionation DTO 150		
		☐ Notice of Info	rmal Patent A			
Attachment(s) ☐ Information Disclosure Statement(s), PTO-1449, Paper		☐ Notice of Info	rmal Patent A	oplication, PTO-152		

Serial Number: 09/007,093

Art Unit: 1644

Part III DETAILED ACTION

1. Applicant is notified that the CRF in this case was entered, however, a correction was needed to properly enter the CRF. The changing of the spelling of the word "Aplication" to Application under (vii) Prior Application Data.

2. Restriction to one of the following inventions is required under 35 U.S.C. 121.

under 35 U.S.C. 121.

Group I. Claims 1-11 and 27-28, drawn to a recombinant conjugate antibody molecule, classified in Class 530, subclass 387.3.

subclass 387.3.

Group II. Claims 12-25, drawn to a nucleic acid molecule, a method of making a polypeptide using said nucleic acid molecules in a vector, said vector expressed in a host cell, classified in a vector, subclass 23.1 and Class 435 subclasses 69.1, 325 and Class 536, subclass 23.1 and Class 435 subclasses 69.1, 325 and 320.1.

The inventions are distinct, each from the other because of the following reasons:

The inventions as grouped in Groups I and II are distinct, each from the other, because they represent different inventive endeavors. The antibody in Group I and the nucleic acid molecule endeavors II are distinct physically and chemically. The inventions in Group II are distinct physically distinct and unrelated structure of these groups have biologically distinct and unrelated structure and function and are separately classified. Therefore, they are patentable one over the other.

- 5. Because a search of these two distinct inventions would not be co-extensive with a search of the others, an examination and search of two or more inventions in a single application would constitute a serious undue burden on the examiner.
- 6. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must remaining the accompanied by a diligently-filed petition under 37 C.F.R. § 1.17(h). § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

Serial Number: 09/007,093

Art Unit: 1644

8. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

- 9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patrick Nolan whose telephone number is (703) 305-1987. The examiner can normally be reached on Monday through Thursday from 8:00 am to 5:30 pm.
- 10. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Christina Chan, can be reached at (703) 305-2973. The FAX number for our group, 1644, is (703) 305-7401. Any inquiry of a general nature relating to the status of this application or proceeding should be directed to the Group receptionist, whose telephone number is (703) 308-0196.

Patrick Nolan, Ph.D. December 21, 1998

> CHRISTINA Y. CHAN SUPERVISORY PATENT EXAMINER GROUP 1800 / 6 (CV)